Valeant Pharma (VRX) Misses Dramatically Reduced Expectations - BMO

Valeant (VRX) PT Cut to $40 at Canaccord Genuity

Canaccord Genuity analyst Neil Maruok reiterated a Hold rating and lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to $40.00 (from $75.00).

Maruok commented, "guidance was even lower than our base-case scenario and we believe has begun to erode investor confidence in Valeants underlying business. We believe that the implementation of the partnership with Walgreens,... More

UPDATE: Piper Jaffray Downgrades Valeant Pharmaceuticals (VRX) to Underweight

(Updated - March 15, 2016 11:20 AM EDT)

Piper Jaffray downgraded Valeant Pharmaceuticals (NYSE: VRX) from Neutral to Underweight. Analyst David Amsellem called Valeant a "broken company" and noted trouble spots across a number of segments.

Amsellem explained the downgrade, "VRX reported 4Q15 adjusted... More

Valeant Pharma (VRX) Results Suggest Disruption in the Business - Evecore ISI's Raffat

Evercore ISI analyst, Umer Raffat, commented on Valeant Pharma (NYSE: VRX) after the call.

"I think it will be an understatement to say that this has clearly been a very humbling call for me," he said.

".. today's results suggests that while... More

Valeant Pharma (VRX) Conference Call Ends

Valeant Pharma (NYSE: VRX) brutal conference call ends. With shares down 36.7% traders will be looking for the stock to possibly rally later in the session.

The Single Most Important Catalyst for Valeant Pharma (VRX) Near-Term...

Valeant Pharma (NYSE: VRX) is down 15% after posting unaudited fourth quarter result and disappointing 2016 guidance. However, according to Evecore ISI analyst Umer Raffat, the single most important catalyst for Valeant near-term is timing for covenants/10-K filing to avoid default .

The all-important date of a default is March 30th + 30 days, so April 29.

Covenant... More

Valeant Pharma (VRX) Won't File 10-K Within 15-Day Extension Period

Valeant Pharma (NYSE: VRX) disclosed the following on Tuesday:

Item 2.02 Results of Operations and Financial Condition

On March 15, 2016, Valeant Pharmaceuticals International, Inc. (the Company) issued a press release announcing preliminary unaudited financial results for the fourth quarter ended December 31, 2015. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

The fourth quarter 2015 results are preliminary because, as previously announced, the Company has delayed the filing of its Annual Report on Form 10-K for the year ended December 31, 2015 pending completion of the Companys... More

Valeant Pharma (VRX) Misses Q4 EPS by 11c; Cuts Q1, FY16 Outlook

Valeant Pharma (NYSE: VRX) reported Q4 EPS of $2.50, $0.11 worse than the analyst estimate of $2.61. Revenue for the quarter came in at $2.8 billion versus the consensus estimate of $2.75 billion.

GUIDANCE:

Valeant Pharma sees Q1 2016 EPS of $1.30 - $1.55, versus prior guidance of $2.35 - $2.55 and the consensus of $2.63. Valeant Pharma sees Q1 2016 revenue of $2.3 - $2.4 billion, versus prior guidance of $2.8 - $3.1 billion and the consensus of $2.82 billion.

Valeant Pharma sees FY2016 EPS... More